Switching from Fingolimod to Ocrelizumab in Multiple Sclerosis
When switching from fingolimod to ocrelizumab, use a short washout period of less than 1 month (ideally <21 days) to minimize disease reactivation risk, complete necessary vaccinations before starting fingolimod cessation, check baseline labs including CBC with differential and liver function tests, and initiate ocrelizumab with standard dosing of 300 mg IV separated by 2 weeks for the first dose.
Washout Period: The Critical Decision
The washout period between fingolimod and ocrelizumab is the most crucial element of this transition. A washout period of less than 21 days is strongly recommended 1. The evidence is clear: longer washout periods dramatically increase disease reactivation risk.
- Optimal timing: <21 days washout 1
- Maximum acceptable: 1 month 2
- Risk threshold: Washout periods exceeding 26 days significantly increase relapse risk in the first 6 months after ocrelizumab initiation 3
The biological rationale is straightforward: fingolimod sequesters lymphocytes in lymph nodes, and upon cessation, these cells rapidly re-enter circulation, potentially triggering disease reactivation. A study demonstrated that 55% of patients with washout periods >21 days experienced relapses during the washout, compared to 0% with shorter washouts 1. Another analysis showed a 9-fold increased risk of confirmed disability progression with 2-6 month washouts compared to <1 month 4.
Critical pitfall: Do not wait for complete lymphocyte normalization before starting ocrelizumab. Starting ocrelizumab while lymphocyte counts remain suppressed from fingolimod may actually reduce its initial effectiveness 5, but this risk is far outweighed by the danger of prolonged washout-related disease reactivation.
Pre-Switch Vaccinations
Complete all necessary vaccinations before stopping fingolimod, as both medications cause immunosuppression 6.
- Live/live-attenuated vaccines: Complete at least 4 weeks before ocrelizumab initiation 6
- Non-live vaccines: Complete at least 2 weeks before ocrelizumab initiation (whenever possible) 6
- VZV status: Check varicella zoster virus antibodies; if negative and no confirmed chickenpox history, vaccinate before the switch 7
The rationale: Ocrelizumab depletes B cells for 6+ months, severely impairing vaccine responses 8. Fingolimod also reduces vaccine efficacy but to a lesser degree. Therefore, vaccinate while still on fingolimod or during the brief washout period.
Baseline Laboratory Monitoring
Obtain these labs before initiating ocrelizumab:
- Complete blood count with differential: Establish baseline lymphocyte counts
- Hepatitis B surface antigen, core antibody, and surface antibody: Screen for hepatitis B reactivation risk 6
- Liver function tests: AST, ALT, bilirubin 7
- Immunoglobulin levels (IgG, IgM, IgA): Baseline for monitoring hypogammaglobulinemia risk 9
- Pregnancy test: For women of childbearing potential 6
Ocrelizumab Dosing Schedule
Initial dosing: 300 mg IV infusion, followed by a second 300 mg IV infusion 2 weeks later (total 600 mg for first dose) 6
Maintenance dosing: 600 mg IV infusion every 6 months thereafter 6
Infusion protocol:
- Premedicate with methylprednisolone 100 mg IV (or equivalent) approximately 30 minutes before each infusion 6
- Consider antihistamine premedication (e.g., diphenhydramine) to reduce infusion reaction risk
- First infusion: Administer over approximately 2.5 hours
- Subsequent infusions: Can be given over 2 hours if first infusion tolerated 6
- Monitor for at least 1 hour post-infusion for infusion reactions 6
High-Risk Period: First 6 Months
Patients switching from fingolimod face elevated relapse risk specifically in the first 3 months after ocrelizumab initiation 3. This risk is nearly 9-fold higher compared to treatment-naive patients starting ocrelizumab, but only when washout exceeds 26 days 3.
Monitoring strategy during months 0-6:
- Clinical assessment monthly for first 3 months
- Brain MRI at 3-6 months to detect subclinical activity
- Educate patients to report new neurological symptoms immediately
- Consider bridging corticosteroids during washout if high disease activity (though not standard practice)
Ongoing Monitoring After Ocrelizumab Initiation
Every 6 months (before each infusion):
- CBC with differential (monitor for lymphopenia, though not typically treatment-limiting) 9
- Liver function tests
- Immunoglobulin levels (IgG, IgM, IgA) - particularly important as hypogammaglobulinemia risk increases with cumulative exposure 9
Annually:
- Brain MRI to assess disease activity 10
As clinically indicated:
- Screen for infections (respiratory, urinary, herpes reactivation) 6
- Monitor for progressive multifocal leukoencephalopathy (PML) symptoms: progressive weakness, vision changes, cognitive changes 6
Special Considerations
Infection risk: Both fingolimod and ocrelizumab increase infection susceptibility. The transition period requires vigilance, but infections during the switch are uncommon with appropriate washout timing 1.
B-cell depletion: Ocrelizumab depletes CD19+ B cells within 14 days of first infusion, with depletion lasting 6+ months 6. This is the intended mechanism but necessitates infection monitoring.
Contraception: Women of childbearing potential must use effective contraception during ocrelizumab treatment and for 6 months after the last infusion 6.
Disease activity predictors beyond 6 months: After the initial high-risk period, age <40 years, male sex, and EDSS ≥2 predict ongoing disease activity on ocrelizumab, independent of prior fingolimod use 3.